BCIQ Profiles

Company Profile Report

Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.).

Skyhawk uses its SkySTAR platform to develop small molecules capable

Read the full 510 word article

How to gain access

Continue reading with a
two-week free trial.